MedTrace Logo

COVID-19 Vaccine Response in Sickle Cell Disease

NCT05139992 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2025-02-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the antibody response to COVID-19 vaccination in a cohort of patients with sickle cell disease (SCD) and to assess vaccine and SCD related complications around the time of vaccination.

Conditions

Interventions

BIOLOGICAL

COVID-19 Vaccine

Vaccination against SARS-CoV-2 administered as part of standard of care

Sponsors & Collaborators

Principal Investigators

  • Charles Abrams, MD · University of Pennsylvania

  • Sophie Lanzkron, MD · Johns Hopkins University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05139992 on ClinicalTrials.gov